TY - JOUR
T1 - Efficient production of erythroid, megakaryocytic and myeloid cells, using single cell-derived iPSC colony differentiation
AU - Hansen, Marten
AU - Varga, Eszter
AU - Aarts, Cathelijn
AU - Wust, Tatjana
AU - Kuijpers, Taco
AU - von Lindern, Marieke
AU - van den Akker, Emile
PY - 2018
Y1 - 2018
N2 - Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical application. Although there are multiple ways to differentiate human iPSCs towards hematopoietic lineages, there is a need to develop reproducible and robust protocols. Here we introduce an efficient way to produce three major blood cell types using a standardized differentiation protocol that starts with a single hematopoietic initiation step. This system is feeder-free, avoids EB-formation, starts with a hematopoietic initiation step based on a novel single cell-derived iPSC colony differentiation and produces multi-potential progenitors within 8–10 days. Followed by lineage-specific growth factor supplementation these cells can be matured into well characterized erythroid, megakaryocytic and myeloid cells with high-purity, without transcription factor overexpression or any kind of pre-purification step. This standardized differentiation system provides a simple platform to produce specific blood cells in a reproducible manner for hematopoietic development studies, disease modelling, drug testing and the potential for future therapeutic applications.
AB - Hematopoietic differentiation of human induced pluripotent stem cells (iPSCs) provide opportunities not only for fundamental research and disease modelling/drug testing but also for large-scale production of blood effector cells for future clinical application. Although there are multiple ways to differentiate human iPSCs towards hematopoietic lineages, there is a need to develop reproducible and robust protocols. Here we introduce an efficient way to produce three major blood cell types using a standardized differentiation protocol that starts with a single hematopoietic initiation step. This system is feeder-free, avoids EB-formation, starts with a hematopoietic initiation step based on a novel single cell-derived iPSC colony differentiation and produces multi-potential progenitors within 8–10 days. Followed by lineage-specific growth factor supplementation these cells can be matured into well characterized erythroid, megakaryocytic and myeloid cells with high-purity, without transcription factor overexpression or any kind of pre-purification step. This standardized differentiation system provides a simple platform to produce specific blood cells in a reproducible manner for hematopoietic development studies, disease modelling, drug testing and the potential for future therapeutic applications.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85046641256&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29751281
U2 - https://doi.org/10.1016/j.scr.2018.04.016
DO - https://doi.org/10.1016/j.scr.2018.04.016
M3 - Article
C2 - 29751281
SN - 1873-5061
VL - 29
SP - 232
EP - 244
JO - Stem Cell Research
JF - Stem Cell Research
ER -